ABSTRACT
A recently published, large, randomized study,
MATRIX (Minimizing Adverse Haemorrhagic
Events by TRansradial Access Site and Systemic Implementation of angioX) (1), compared transradial access (TRA) to transfemoral access (TFA) in patients presenting with acute coronary syndromes (ACS) who were referred for percutaneous coronary intervention (PCI). The results of this trial have been interpreted to suggest that TRA is superior to TFA in reducing net adverse clinical events (NACE) through a reduction of bleeding and mortality. This conclusion could significantly affect our practice guidelines and lead to a strong recommendation that the approach of choice for PCI in ACS is radial rather than femoral. Hence, this trial has significant implications for both PCI centers and interventionalists, and it could have an effect on medical practice and education. However, the MATRIX trial has serious shortcomings that need to be considered.
The MATRIX trial randomly assigned 8,404 ACS patients to TRA (n ¼ 4,197) or TFA (n ¼ 4,207) to compare clinical outcomes in patients referred for coronary angiography and PCI (1). The study was designed with 2 30-day coprimary endpoints: 1) major adverse cardiovascular events (MACE), defined as all-cause mortality, myocardial infarction, or stroke;
and 2) NACE, defined as major bleeding unrelated to coronary artery bypass graft surgery or major adverse cardiovascular events. Major bleeding was classified according to the Bleeding Academic Research Consortium (2). Because of multiple comparisons, the 2-sided a was pre-specified at 0.025 for each primary endpoint. MACE was recorded in 8.8% of patients assigned to TRA and in 10.3% of patients assigned to TFA (p ¼ 0.03); this was interpreted as nonsignificant.
However, the rate of NACE was significantly lower in patients assigned to TRA compared to TFA (9.7% vs.
11.7%, respectively; p ¼ 0.009); a difference said to be driven by major bleeding (1.6% vs. 2.3%; p ¼ 0.013) and all-cause mortality (1.6% vs. 2.2%; p ¼ 0.045). The authors suggest that the benefits associated with implementation of TRA for the treatment of ACS "might be especially relevant for countries such as the USA where use of the radial approach is currently uncommon" (3). However, a critical appraisal of the MATRIX trial's results will cast a word of caution before accepting the authors' conclusions.
First, it is quite clear that the outcomes were dependent upon the center's experience at performing PCI. A center's experience is determined by its access preference (i.e., the proportion of TRA vs. TFA) and by its annual PCI volume; in addition, the experience levels of the operator, the catheteriza- In fact, the only time TRA is significantly better than TFA occurs when the results are considered only for centers with a high proportion (80.0% to 98.0%) of PCIs done using TRA. There is no difference even when the proportion of TRA is as high as 79% (14.9% to 79.0%). Although the labels "low," "intermediate,"
and "high" are used, more appropriate labels would be "intermediate," "high," and "very high," respectively, given the percentages that they represent. It is only in the "very high" group that there is a difference favoring TRA, and it occurs in centers with essentially no or very limited TFA experience. One could argue that operators in these centers have optimal TRA skills that enable the benefit of TRA to be more evident; however, it remains unexplained why the absolute rates of MACE and NACE in the TRA group were unexpectedly higher in centers with a "high" proportion of radial procedures compared with those in the "low" and "intermediate" centers.
Furthermore, in the "high" radial proportion centers, the rates of MACE and NACE in the TFA group were excessive, 15.5% and 17.1%, respectively, compared with the rates reported for centers with a "low" or Le May et al.
3) the choice and duration of anticoagulant therapy; and 4) the likelihood of bleeding (6 Interestingly, a similar study, the RIVAL (RadIal Vs femorAL access for coronary intervention) trial (7) 
Radial Versus Femoral Access in ACS
S E P T E M B E R 2 0 1 5 : 1 4 0 5 -9
